[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337607-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-337607-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","the-effects-of-aurora-kinase-inhibition-on-thyroid-cancer-growth-and-sensitivity-to-mapk-directed-therapies","The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies","","Thyroid cancer ranks among the deadliest endocrine malignancies, with rising incidence. Despite common BRAF mutations and use of MAPK-pathway targeting in related diseases, advanced papillary thyroid cancer lacks effective options, and resistance limits benefits even after approved BRAF plus MEK1/2 inhibition. This study evaluates combined BRAF and MEK1/2 inhibition in BRAF-mutant thyroid cancer cell lines, identifying Aurora kinase B downregulation in MEK1/2-sensitive cells and demonstrating that co-inhibition of AURKB with MEK1/2, as well as AURKB with ERK1/2, slows growth and induces apoptosis.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-effects-of-aurora-kinase-inhibition-on-thyroid-cancer-growth-and-sensitivity-to-mapk-directed-therapies/337607/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-effects-of-aurora-kinase-inhibition-on-thyroid-cancer-growth-and-sensitivity-to-mapk-directed-therapies/337607.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main objective of the study?","Question",{"text":63,"@type":64},"To determine how Aurora kinase inhibition affects thyroid cancer growth and sensitivity to MAPK-directed therapies, particularly in relation to BRAF-mutant disease and MEK1/2 inhibitor response.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the researchers assess therapy response?",{"text":68,"@type":64},"They measured growth and signaling outcomes from combined BRAF and MEK1/2 inhibition across a panel of BRAF-mutant thyroid cancer cell lines, and used RNA-sequencing to explore mechanisms associated with sensitivity versus resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism related to Aurora Kinase B was linked to sensitivity?",{"text":72,"@type":64},"MEK1/2 inhibition downregulated Aurora Kinase B (AURKB) in MEK1/2-sensitive cells but not in resistant cells, suggesting AURKB as a potential resistance-associated node.",{"name":74,"@type":61,"acceptedAnswer":75},"What therapeutic combination did the paper support?",{"text":76,"@type":64},"Combined AURKB and ERK1/2 inhibition (and also AURKB together with MEK1/2 inhibition) reduced cell growth and induced apoptosis in BRAF-mutant thyroid cancer cell lines, supporting a potential combination therapy strategy.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},337607,1790159850,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","CANCER BIOLOGY & THERAPY  \n2024, VOL. 25, NO. 1, 2332000 [https://doi.org/10.1080/15384047.2024.2332000](https://doi.org/10.1080/15384047.2024.2332000)  \nRESEARCH PAPER  \nThe effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies  \nHannah M. Hicks a, Veronica L. Nassara, Jane Lunda, Madison M. Rose a, and Rebecca E. Schweppe a,b  \naDivision of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA; bUniversity of Colorado Cancer Center, University of Colorado School of Medicine, Aurora, CO, USA  \nABSTRACT  \nThyroid cancer is one of the deadliest endocrine cancers, and its incidence has been increasing. While mutations in BRAF are common in thyroid cancer, advanced PTC patients currently lack therapeutic options targeting the MAPK pathway, and despite the approved combination of BRAF and MEK1/2 inhibition for BRAF-mutant ATC, resistance often occurs. Here, we assess growth and signaling responses to combined BRAF and MEK1/2 inhibition in a panel of BRAF-mutant thyroid cancer cell lines. We first showed that combined BRAF and MEK1/2 inhibition synergistically inhibits cell growth in four out of six of the-BRAF-mutant thyroid cancer cell lines tested. Western blotting showed that the MAPK pathway was robustly inhibited in all cell lines. Therefore, to identify potential mechanisms of resistance, we performed RNA-sequencing in cells sensitive or resistant to MEK1/2 inhibition. In response to MEK1/2 inhibition, we identified a downregulation of Aurora Kinase B (AURKB) in sensitive but not resistant cells. We further demonstrated that combined MEK1/2 and AURKB inhibition slowed cell growth, which was phenocopied by inhibiting AURKB and ERK1/2 . Finally, we show that combined AURKB and ERK1/2 inhibition induces apoptosis in BRAF-mutant thyroid cancer cell lines, together suggesting a potential combination therapy for BRAF-mutant thyroid cancer patients.  \nARTICLE HISTORY  \nReceived 24 April 2023 Revised 8 August 2023 Accepted 14 March 2024  \nKEYWORDS  \nAurora Kinase; MAP kinase; thyroid cancer; drug resistance; BRAF; ERK1/2  \nIntroduction  \nThyroid cancer is the most common endocrine malignancy, and its prevalence has been increasing over the last four decades.1 More aggressive subtypes of thyroid cancer, including advanced papillary thyroid cancer (PTC), poorly differentiated thyroid cancer (PDTC), and anaplastic thyroid cancer (ATC), are undifferentiated and therefore radioiodine-refractory.2–4 Thus, new therapies are needed to treat these tumors.5,6  \nMutations of the MAP Kinase (MAPK) pathway, primarily in BRAF-V600E are highly prevalent in thyroid cancer.7–9 While pharmacologic inhibition of BRAF has shown some success in melanoma with activating BRAF mutations,10 similar trials in thyroid cancer have produced mixed results.11–14 Major limitations oftherapy with single agent BRAF inhibition include intrinsic (upfront) and acquired resistance. Acquired resistance most often occurs through downstream re-activation of the MAPK pathway through the release of negative feedback.15–19 This has led to the FDA approval of combined BRAF and MEK1/2 inhibition in melanoma.20–22 More recently, combined BRAF and MEK1/2 inhibition was approved for ATC based on a small phase II study of the BRAF inhibitor, dabrafenib (BRAFi), in combination with the MEK1/2 inhibitor, trametinib (MEKi), which showed a response rate of 69% in 16 BRAF-mutant ATC patients,14 seven of which were durable at the time of reporting. However, the observed response rate has only been 56% in ATC, and based on studies in melanoma, it is expected that resistance  \nwill develop.23 Of interest, advanced PTC exhibits intrinsic resistance and a similar trial in BRAF-mutant PTC failed to show significant benefit for a BRAFi/MEKi combination compared to BRAFi alone.24 Thus, new therapeutic strategies are needed to combat mechanisms of resistance.  \nHere, we identif","cbCaifDSXr3RVCmI","https://ap.wps.com/l/cbCaifDSXr3RVCmI","pdf",3682563,"English","# Abstract\n# Introduction\n# Materials and methods\n## Reagents\n# Article history\n# Keywords","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To determine how Aurora kinase inhibition affects thyroid cancer growth and sensitivity to MAPK-directed therapies, particularly in relation to BRAF-mutant disease and MEK1/2 inhibitor response.\"},{\"question\":\"How did the researchers assess therapy response?\",\"answer\":\"They measured growth and signaling outcomes from combined BRAF and MEK1/2 inhibition across a panel of BRAF-mutant thyroid cancer cell lines, and used RNA-sequencing to explore mechanisms associated with sensitivity versus resistance.\"},{\"question\":\"What mechanism related to Aurora Kinase B was linked to sensitivity?\",\"answer\":\"MEK1/2 inhibition downregulated Aurora Kinase B (AURKB) in MEK1/2-sensitive cells but not in resistant cells, suggesting AURKB as a potential resistance-associated node.\"},{\"question\":\"What therapeutic combination did the paper support?\",\"answer\":\"Combined AURKB and ERK1/2 inhibition (and also AURKB together with MEK1/2 inhibition) reduced cell growth and induced apoptosis in BRAF-mutant thyroid cancer cell lines, supporting a potential combination therapy strategy.\"}]","The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies | PDF",1790019762,25,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c52e4b9fa2cf494a391d8365eac99f2.webp",983,1280,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/955d28dba4907e97e1c35bcae45d1834.webp",982,1278,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e601e1022148101ac51adc64d4cd646.webp",981,1277,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91157857196be87a3b301288dbdb5bb3.webp",980,1276]